Intra-Cellular Therapies (ITCI) signed a definitive agreement with pharma bigwig Johnson & Johnson (JNJ) . Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion.A commercial-stage biotech company, Intra-Cellular is focused on developing and marketing novel drugs targeting neuropsychiatric and neurological disorders.The acquisition will add ITCI’s sole marketed drug, Caplyta, which is approved for two indications — schizoph ...

Intra-Cellular Therapies (ITCI) shares rallied 34.1% in the last trading session to close at $127.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.3% gain over the past four weeks.The surge in stock price came after pharma giant J&J announced its intent to acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion. The deal is expected to be completed before t ...

Shares of Intra-Cellular Therapies (ITCI) rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz (SDZNY) regarding the Caplyta (lumateperone) patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version of Caplyta in the United States before applicable patents expire. The litigation is currentl ...

Key TakeawaysShares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company.Intra-Cellular shareholders will get $132 per share, valuing the company at about $14.6 billion.Intra-Cellular Therapies sells one drug treating schizophrenia and bipolar I and II depression, Caplyta, and has trials ongoing for others that could treat Alzheimer's Disease and Parkinson's Disease. Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premark ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% loss over the past four weeks.The sudden soaring of the stock price was observed after ITCI announced that it has entered into a settlement agreement with Sandoz regarding the Caplyta (lumateperone) patent litigation. The settlement agreement resolves the patent litigation brought ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in pe ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of therapies with $5 billion+ potential in pe ...

BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies' product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jerse ...

BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies’ product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jers ...

BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA. The live and archived webcast can be accessed under " ...